Meningococcal B vaccine study for asplenia
Treatments studied
Part of Infections clinical trials.
This study tests a meningococcal B vaccine in adults who have had their spleen removed or have a spleen that doesn't work well (asplenia). It will compare how well the vaccine works in these patients versus healthy adults to see if it provides good protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You either have no working spleen (asplenia) or are a healthy volunteer
- You have not had a meningococcal B vaccine before
- You have no serious allergies to vaccines
- You are not pregnant or breastfeeding, and if female, you agree to use birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
This trial tests two different booster shots for meningitis B in young adults who already got the Bexsero vaccine at least 2.5 years ago. The goal is to see which booster works best to keep you protected.
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.
Hear when a new Splenectomy; Status trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.